Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 June 2024 | Story Carmenita Redcliffe-Paul
Global Citizen Invitation Prof Thuli Madonsela 4 July 2024

The University of the Free State (UFS) and the South African Chamber of Commerce United Kingdom (SACC UK) are pleased to present a Global Citizen Series conversation, South Africa’s Future in Focus: the post-election impact on social justice, service delivery, higher education, and the economy, from the perspective of Prof Thuli Madonsela, Director of the Centre for Social Justice in the Faculty of Law at Stellenbosch University and Professor of Law in the Law Trust Research Chair in Social Justice Studies.

As part of the Global Citizen Webinar Series, Prof Madonsela – a member of the International Anticorruption Advisory Council and Global Justice Leaders – will join UFS Vice-Chancellor and Principal, Prof Francis Petersen, and SACC UK Chairperson, Sharon Constançon, for a conversation that explores what the future holds for social justice, service delivery, higher education, and the economy in South Africa.

After thirty years of democracy, South Africans once again made their mark on 29 May 2024 in one of the most pivotal elections since 1994. Join us in person during the Free State Arts Festival or online as we explore South Africa’s Future in Focus: The post-election impact on social justice, service delivery, higher education, and the economy.

Date: Thursday 4 July 2024
In-person event SA time: 18:00-20:00 SAST, Centenary Complex, UFS Bloemfontein Campus
Webinar SA time: 18:30-19:30 / UK time: 17:30-18:30

The livestream link will be shared with those who RSVP

Enquiries: Tebello Leputla - leputlatb@ufs.ac.za +27 51 401 3966

About Prof Thuli Madontsela

Prof Thuli (Thulisile) Madonsela is the Director of the Centre for Social Justice (CSJ) in the Faculty of Law at Stellenbosch University and Professor of Law in the Law Trust Research Chair in Social Justice Studies. She is the founder of the Thuma Foundation for Democracy Leadership and Literacy and a member of the African Academy of Sciences. She was recently appointed to the UN Scientific Advisory Board and as Chairperson of Cities Alliance. She is a member of the International Anticorruption Advisory Council and Global Justice Leaders.

The former Public Protector of South Africa and full-time Commissioner in the South African Law Reform Commission was one of the 11 technical experts who helped draft the South African Constitution, and is a co-architect of several constitutionally mandated laws, including the Equality Act, Employment Equity Act, and the Promotion of Administrative Justice Act. She has an extensive background in applied constitutional, social justice, and administrative law principles, mainly based on her years of public service and her investigation of improper conduct in state affairs as Public Protector. A regular sought-after keynote speaker, Prof Madonsela has written, taught, presented papers, and published on these matters and ethical leadership, good governance, and gender mainstreaming for decades.

Prof Madonsela helped draft several international human rights instruments at UN, AU, and SADC levels, as well as country reports on such matters. She currently teaches Constitutional Law, Social Justice Law, Administrative Law, and Constitutional Governance and Ethical Leadership. She holds eight honorary law doctorates, in addition to two law degrees, a Harvard Advanced Leadership Certificate, and other postgraduate qualifications.

Named one of Time’s 100 most influential people in the world in 2014, Prof Madonsela’s global recognition includes more than 70 awards, including Rotary’s Paul Harris award, the Commonwealth Lawyers Truth and Justice award, and the global ACFE’s Cressy award. Prof Madonsela is a mother of two, a philanthropist, and an avid mountaineer who has summited Mt Kilimanjaro twice under the #Trek4Mandela-#Caring4Girls anti-period poverty campaign and the Musa Plan for Social Justice, and regularly hikes for the #Action4Inclusion campaign, a quest to end student debt.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept